Tag: journal

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

James Altucher's free presentation walks through what the unusually large underwriting group signals about the scale of the SpaceX listing.

As SpaceX prepares to list on the Nasdaq in June, the early technology trend spotter walks through the story behind one of the most anticipated public offerings in years.

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

James Altucher walks through what Starlink's expanding constellation signals about the company's future and why most investors haven't connected the dots.